REFERENCES
1. Liu J, Barrett JS, Leonardi ET, et al. Natural History and Real-World Data in Rare Diseases: Applications, Limitations, and Future Perspectives. J Clin Pharmacol . 2022;62 Suppl 2:S38-S55. doi:10.1002/jcph.2134
2. Hiramatsu K, Barrett A, Miyata Y, PhRMA Japan Medical Affairs Committee Working Group 1. Current Status, Challenges, and Future Perspectives of Real-World Data and Real-World Evidence in Japan.Drugs Real World Outcomes . 2021;8(4):459-480. doi:10.1007/s40801-021-00266-3
3. Pharmaceuticals and Medical Devices Agency. Accessed June 25, 2023. https://www.pmda.go.jp/
4. Tsuchiya M, Obara T, Miyazaki M, Noda A, Takamura C, Mano N. The quality assessment of the Japanese Adverse Drug Event Report database using vigiGrade. Int J Clin Pharm . 2020;42(2):728-736. doi:10.1007/s11096-020-00969-7
5. Suga Y, Uchida M, Suzuki S, et al. Current Status of Adverse Events Related with Opioid Analgesics in Japan: Assessment Based on Japanese Adverse Drug Event Report Database. Biol Pharm Bull . 2019;42(5):801-806. doi:10.1248/bpb.b18-00997
6. Wilson AM, Thabane L, Holbrook A. Application of data mining techniques in pharmacovigilance. Br J Clin Pharmacol . 2004;57(2):127-134. doi:10.1046/j.1365-2125.2003.01968.x
7. Lau EMT, Giannoulatou E, Celermajer DS, Humbert M. Epidemiology and treatment of pulmonary arterial hypertension. Nat Rev Cardiol . 2017;14(10):603-614. doi:10.1038/nrcardio.2017.84
8. Zhang ZQ, Zhu SK, Wang M, et al. New progress in diagnosis and treatment of pulmonary arterial hypertension. J Cardiothorac Surg . 2022;17(1):216. doi:10.1186/s13019-022-01947-y
9. Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med . 2013;369(9):809-818. doi:10.1056/NEJMoa1213917
10. Sitbon O, Channick R, Chin KM, et al. Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med . 2015;373(26):2522-2533. doi:10.1056/NEJMoa1503184
11. Galiè N, Barberà JA, Frost AE, et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med . 2015;373(9):834-844. doi:10.1056/NEJMoa1413687
12. Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J . 2023;61(1):2200879. doi:10.1183/13993003.00879-2022
13. Pitre T, Su J, Cui S, et al. Medications for the treatment of pulmonary arterial hypertension: a systematic review and network meta-analysis. Eur Respir Rev . 2022;31(165):220036. doi:10.1183/16000617.0036-2022
14. Leber L, Beaudet A, Muller A. Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identification of the most accurate estimates from a systematic literature review. Pulm Circ . 2021;11(1):2045894020977300. doi:10.1177/2045894020977300
15. Preston IR, Roberts KE, Miller DP, et al. Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL). Circulation . 2015;132(25):2403-2411. doi:10.1161/CIRCULATIONAHA.115.018435
16. Ogawa A, Satoh T, Tamura Y, Fukuda K, Matsubara H. Survival of Japanese Patients With Idiopathic/Heritable Pulmonary Arterial Hypertension. Am J Cardiol . 2017;119(9):1479-1484. doi:10.1016/j.amjcard.2017.01.015
17. Tamura Y, Kumamaru H, Satoh T, et al. Effectiveness and Outcome of Pulmonary Arterial Hypertension-Specific Therapy in Japanese Patients With Pulmonary Arterial Hypertension. Circ J . 2017;82(1):275-282. doi:10.1253/circj.CJ-17-0139
18. Hoeper MM, Pausch C, Grünig E, et al. Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry. Eur Respir J . 2022;59(6):2102024. doi:10.1183/13993003.02024-2021
19. Ogawa A, Ejiri K, Matsubara H. Long-term patient survival with idiopathic/heritable pulmonary arterial hypertension treated at a single center in Japan. Life Sci . 2014;118(2):414-419. doi:10.1016/j.lfs.2014.01.077
20. Tamura Y, Tamura Y, Taniguchi Y, et al. Clinical Management and Outcomes of Patients With Portopulmonary Hypertension Enrolled in the Japanese Multicenter Registry. Circ Rep . 2022;4(11):542-549. doi:10.1253/circrep.CR-22-0098
21. Tamura Y, Kumamaru H, Inami T, et al. Changes in the Characteristics and Initial Treatments of Pulmonary Hypertension Between 2008 and 2020 in Japan. JACC Asia . 2022;2(3):273-284. doi:10.1016/j.jacasi.2022.02.011
22. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med . 1996;334(5):296-301. doi:10.1056/NEJM199602013340504
23. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol . 2002;40(4):780-788. doi:10.1016/s0735-1097(02)02012-0
24. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation . 2002;106(12):1477-1482. doi:10.1161/01.cir.0000029100.82385.58
25. Chaumais MC, Jobard M, Huertas A, et al. Pharmacokinetic evaluation of continuous intravenous epoprostenol. Expert Opin Drug Metab Toxicol . 2010;6(12):1587-1598. doi:10.1517/17425255.2010.534458
26. Bourge RC, Waxman AB, Gomberg-Maitland M, et al. Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System: Results of the DelIVery for PAH Trial. Chest . 2016;150(1):27-34. doi:10.1016/j.chest.2015.11.005
27. Richter MJ, Harutyunova S, Bollmann T, et al. Long-term safety and outcome of intravenous treprostinil via an implanted pump in pulmonary hypertension. J Heart Lung Transplant . 2018;37(10):1235-1244. doi:10.1016/j.healun.2018.06.006
28. Olschewski H, Simonneau G, Galiè N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med . 2002;347(5):322-329. doi:10.1056/NEJMoa020204
29. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol . 2003;41(12):2119-2125. doi:10.1016/s0735-1097(03)00463-7
30. Kloner RA, Hutter AM, Emmick JT, Mitchell MI, Denne J, Jackson G. Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol . 2003;42(10):1855-1860. doi:10.1016/j.jacc.2003.09.023
31. Hoeper MM, Al-Hiti H, Benza RL, et al. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. Lancet Respir Med . 2021;9(6):573-584. doi:10.1016/S2213-2600(20)30532-4
32. Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.Circulation . 2008;117(23):3010-3019. doi:10.1161/CIRCULATIONAHA.107.742510
33. Humbert M, Segal ES, Kiely DG, Carlsen J, Schwierin B, Hoeper MM. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J . 2007;30(2):338-344. doi:10.1183/09031936.00138706
34. Ulrich S, Saxer S, Hasler ED, et al. Effect of domiciliary oxygen therapy on exercise capacity and quality of life in patients with pulmonary arterial or chronic thromboembolic pulmonary hypertension: a randomised, placebo-controlled trial. Eur Respir J . 2019;54(2):1900276. doi:10.1183/13993003.002762019
35. Tamura Y, Kimura M, Takei M, et al. Oral vasopressin receptor antagonist tolvaptan in right heart failure due to pulmonary hypertension. Eur Respir J . 2015;46(1):283-286. doi:10.1183/09031936.00044915
Table 1 Demographics and clinical outcomes of the patients with pulmonary arterial hypertension reported in the Japanese Adverse Drug Event Report database